home / subscribe / donate / tower / books / archives / search / links / feedback / events / faq
|
No Death Squads, No Torture, No Milton Friedman, No "Shock and Awe" Bombing; just Mild-Mannered Liberals from the World Bank and Harvard driving hundreds of thousands of poor people around the world to starvation and suicide. Read P. Sainath's searing special report. Get your copy today by subscribing online or calling 1-800-840-3683 Remember contributions to CounterPunch are tax-deductible. Click here to make a donation. If you find our site useful please: Subscribe Now
|
|
October 16, 2007 Peter
Linebaugh Uri
Avnery October 15, 2007 Gary
Leupp Andy
Worthington Heather
Gray John
Walsh Joshua
Frank Dave
Lindorff Matt
Vidal Ali
Khan Sen.
Russ Feingold Johnny
Barber Website
of the Day October 13 / 14, 2007 Alexander
Cockburn Wajahat
Ali Jeffrey
St. Clair Ralph
Nader David Heleniak Laura Carlsen Brian Cloughley Richard Rhames Ron Jacobs Fred Gardner John Ross Russell Hoffman Missy Beattie Poets' Basement Website of the Day
Cindy
Sheehan Brendan
Cooney Alan
Farago Jan
Oberg M.
Shahid Alam David
Macaray Julia
Kendlbacher Peter
Rost, MD Website
of the Day
Al
Giordano Saul
Landau Jacob
G. Hornberger William
S. Lind Joshua
Frank Josh
Mahan Pat
Williams
October 10, 2007 Michael
Yates Gary
Leupp David
Macaray Alan
Farago Tom
Clifford Col.
Douglas MacGregor Sunsara
Taylor George
Wuerthner Roxanne
Dunbar-Ortiz Michael
Dickinson Website
of the Day
October 9, 2007 Paul
Craig Roberts Andy
Worthington Alan
Farago Brian
Eno David
Rovics Farzana
Versey Andrew
Buncombe Website
of the Day
October 8, 2007 David
Macaray Jeff
Ballinger Brian
Eno Christopher
Brauchli Louay
Safi Matt
Reichel Dave
Lindorff Thomas
P. Healy Martha
Rosenberg Richard
Rhames Website
of the Day
October 6 / 7, 2007 Alexander
Cockburn Norman
Finkelstein James
Bovard Patrick
Cockburn Jeffrey
St. Clair Ralph
Nader Ray
McGovern Saul
Landau Ben
Tripp Terry
Lodge Seth
Sandronsky Kevin
Funk / Steve Fake Missy
Beattie Website
of the Weekend
October 5, 2007 Andy
Worthington David
Macaray Lee
Sustar Dan
La Botz Aaron
Hess William
A. Cook Website
of the Day
October 4, 2007 Uri
Avnery Dave
Marsh Valerio
Volpi Cecilie
Surasky Dave
Lindorff Norman
Solomon Laura
Carlsen Walter
Brasch Ben
Terrall William
S. Lind Website
of the Day
October 3, 2007 Vijay
Prashad Anita
Sinha Winslow
T. Wheeler Sharon
Smith Jeff
Leys Sen.
Russ Feingold Mohamad
Bazzi Brenda
Norrell Robert
Weissman Website
of the Day
October 2, 2007 Ibrahim
Warde Gary
Leupp David
Macaray Conn
Hallinan John
Ross Alan
Farago Sonja
Karkar Niranjan
Ramakrishnan Website
of the Day
October 1, 2007 Al
Giordano Paul
Craig Roberts Moshe Adler Ingmar Lee John V. Walsh Norman Solomon Roger Burbach Ramzy Baroud Stephen Lendman Susie Day Website of the Day
September 29 / 30, 2007 Alexander
Cockburn Uri
Avnery Andrew
Cockburn Jeffrey
St. Clair Wajahat
Ali Andy
Worthington Don
Santina Ralph
Nader Fred
Gardner Seth
Sandronsky Gideon
Levy William
S. Lind Reza
Fiyouzat Richard
Rhames David
Michael Green Zach
Mason Poets'
Basement Website
of the Weekend
September 28, 2007 Kathleen
and Bill Christison Roberto
J. González / Saul
Landau Tom
Clifford Christopher
Brauchli Martha
Rosenberg Dave
Zirin Laray
Polk Binoy
Kampmark James
McEnteer Website
of the Day
September 27, 2007 Alan
Farago Andy
Worthington Jonathan
Cook William
Hughes Ray
McGovern Ron
Jacobs Dave
Lindorff Joshua
Frank Anne
Dachel Website
of the Day
Bill
Quigley Paul
Craig Roberts Jeff
Kisseloff China
Hand Behzad
Yaghmaian Sonja
Karkar Mike
Ferner Col.
Dan Smith Clifton
Ross Brenda
Norrell Website
of the Day
September 25, 2007 Nicole
Colson Uri
Avnery Brendan
Cooney Harry
Browne Marjorie
Cohn David
Macaray Ralph
Nader Dan
Bacher Anthony
Papa Christopher
Ketcham Website
of the Day
September 24, 2007 George
Ciccariello-Maher Saree Makdisi David
Keen Sherwood
Ross Ron
Jacobs Donna
Saggia Mike
Ferner Malini
Johar Schueller Monique
Dols Website
of the Day
Alexander
Cockburn Jennifer
Loewenstein Linn
Washington, Jr. Jeffrey
St. Clair Alan
Farago Brian
Cloughley Robert
Fantina Roxanne
Dunbar-Ortiz Jason
Hribal David
Rosen Mike
Whitney John
V. Walsh Dave
Lindorff David
Michael Green Fred
Gardner Cassandra
Jones Roger
van Zwanenberg Poets'
Basement Website
of the Weekend
September 21, 2007 Karim
Makdisi M.
Shahid Alam Alan
Farago Joshua
Frank Dave
Zirin Kenneth
Couesbouc Dr.
Steffie Woolhandler and Dr. David Himmelstein Ben
Terrall Steve
Fournier Frederico
Fuentes, et al Website
of the Day
September 20, 2007 Kathleen
Christison Zoltan
Grossman Paul
Craig Roberts Stan
Cox Russell
Mokhiber Charles
Modiano Raymond
J. Lawrence Brendan
Cooney Website
of the Day
September 19, 2007 Paul
Craig Roberts Paul
Krassner Sgt.
Martin Smith Seth
Sandronsky Claud
Cockburn Victoria
Buch Robert
Weissman Mike
Ferner Dan
Bacher Website
of the Day
September 18, 2007 Mike
Whitney Alan
Farago John
Ross Ron
Jacobs Alex
Doherty September 17, 2007 Marjorie
Cohn Paul
Craig Roberts Ricardo
Alarcón Marc
Levy Eva
Liddell Website
of the Day Sept. 15-16, 2007 Alexander
Cockburn Vicente
Navarro Mike
Whitney Herman
Mindshaftgap Ellen
Cantarow Jordan
Flaherty Zachary
Hurwitz September 14, 2007 Debbie
Nathan Franklin
Lamb Patrick
Cockburn Farzana
Versey Alan
Farago Hank
Edson September 13, 2007 Patrick
Cockburn Scott
Vest, former Air Force Captain at Minot Andy
Worthington Michael
Baney Dr.
Susan Block September 12, 2007 Paul
Craig Roberts Stan
Goff William
Blum Manuel
Garcia Debbie
Nathan
![]()
![]()
Subscribe Online
|
October 16, 2007 Lilly's Troubled New Anti-DepressantThe Curse of CymbaltaBy MARTHA ROSENBERG It was supposed to replace Prozac profits when the patent expired in 2001 and cash in on the national love affair with antidepressants. But Eli Lilly & Co.'s Cymbalta (duloxetine) seemed cursed from the start. The first antidepressant to be introduced since FDA investigations into suicide/antidepressant links, Cymbalta itself was marred with suicides before it was approved. Five occurred during Cymbalta clinical trials including previously healthy volunteer Traci Johnson who hung herself in Lilly's Indiana University Medical School lab in 2004. "Their posturing was offensive," said the Rev. Joel Barnaby, spokesman for Traci Johnson's family upon hearing Lilly would not delay the drug's planned introduction. "They were saying that this little death certainly should not defame our study or, God forbid, make us miss a deadline for FDA approval." Nor was Traci, "in a depressed state of mind or had a spirit wounded so much that she gave up on life," Mr. Barnaby said. Despite $208 million in sales in its first eight months of marketing thanks to auto suggestive "Depression Hurts" television ads and do-you-have-this-disease? symptom checklists on its web site, Cymbalta's bad buzz didn't go away. A year after Cymbalta hit drug store shelves it was indicted for causing more than twice the rate of suicide attempts in women prescribed the drug for stress urinary incontinence--a use not approved in the US--according to the FDA. Last May, the FDA ordered Lilly to add a black box to Cymbalta warning about suicides and antidepressants in young adults. And in October Lilly was told to "immediately cease" its Cymbalta campaign for diabetic nerve pain--an approve use--which promises "significantly less pain interference with overall functioning." In a letter, the FDA says the claim "has not been demonstrated by substantial evidence or ... clinical experience" nor do the Cymbalta marketing pieces give precautions about liver toxicity or reveal risks for patients with certain conditions. (Lilly spokesman Charlie McAtee said Lilly will take action once it has "more clarity" on FDA objections. Which part of "immediately cease" does he not understand?) Even Lilly's own reps are trashing the drug on the pharma chat room cafepharma.com. "My territory includes a high percent of blue collar beer guzzlers that drive home from work with a six pack on their lap," wrote one anonymous poster. "The Docs around here won't touch Cymbalta." "This product should have never been approved by the FDA. The benefits do not outweigh the risks," wrote another. "That is why there are very few insurance companies that will cover this product. This is the dirtiest product in the anti-depressant class." "Cymbalta will be pulled from the market within the next 2 years due to its major liver damage," predicted another poster. Things wouldn't be so bad for Lilly if its number one drug-- Zyprexa (olanzapine) --wasn't also in trouble. In the last year, doctors learned that side effects of the atypical antipsychotic, taken by 20 million people since 1996, "include diabetes, stroke and death," according to the New York Times. Lilly's own published data shows morbid patient weight gain--30 percent of patients taking Zyprexa gained 22 pounds or more, 16 percent, 66 pounds or more and some gained over 100 pounds--and blood sugar levels that keep increasing with use says the Times--information it hid from doctors and regulators. ("Olanzapine-associated weight gain and possible hyperglycemia is a major threat to the long-term success of this critically important molecule," wrote Lilly Chief Medical Officer Dr. Alan Breier in an 1999 email to employees; "Unless we come clean on this, it could get much more serious than we might anticipate," concurred a group of diabetes doctors Lilly hired to assess the drug's safety in 2000.) Worse, Lilly was caught playing off label roulette with Zyprexa; marketing it for any condition that would stick to the wall instead of the schizophrenia and bipolar disorder for which it was approved. Its Viva Zyprexa campaign marketed unabashedly to older patients with symptoms of dementia--though the drug increases the risk of death in older patients with dementia-related psychosis according to its own label-- earning Lilly 49,000 new prescriptions valued at $300 a month after only three months. (The elderly people might have had undiagnosed schizophrenia offered Lilly's vice president for corporate affairs, Anne Nobles, as a weak excuse.) The campaign then evolved to Zyprexa Limitless and began targeting the set of all people diagnosed as depressed who don't know they are really bipolar yet. At a 2001 sales meeting, Michael Brandick, Zyprexa brand manager, called the new prescriptions, "a pretty sweet incentive," for sales representatives and olanzapine, "the molecule that keeps on giving." Lilly is now paying for its over the top marketing having spent $2 billion since 2004 to settle lawsuits from 28,500 people who blamed diabetes or heart problems on the drug with 1,200 more lawsuits to be resolved. No wonder Lilly "voluntarily" strengthened Zyprexa's warning label in October with tougher language about weight gain and elevated blood sugar after "reviewing more data from internal tests and major outside studies." Of course creating diabetes with one pill and treating it with another may look like self dealing. But Lilly's vision isn't that narrow. It's also marketing ADHD drugs to China's kids, Zyprexa to adolescents and Cymbalta to fibromyalgia patients. Fibromyalgia no doubt hurts too. Martha Rosenberg is staff cartoonist on the Evanston
Roundtable. She can be reached at mrosenberg@evmark.org ![]()
|
How the Press Led the US into War ![]() Buy End Times Now! CounterPunch Books of the Crossroads: HOW THE IRISH INVENTED SLANG By Daniel Cassidy AMERICAN BOOK AWARD! ![]() Click Here to Buy! Click Here for Dates & Venues Michael Neumann's Devastating Rebuttal of Alan Dershowitz ![]() Click Here to Buy! Saul Landau's Bush and Botox World with a Foreword by Gore Vidal ![]() Click Here to Order! How They Made a Killing on the War on Terrorism ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() The Occupation by Patrick Cockburn ![]() ![]() ![]() Humanitarian Imperialism By Jean Bricmont ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() CITY BEAUTIFUL By Tennessee Reed ![]() ![]() ![]() ![]() ![]() ![]() Bruce Springsteen On Tour By Dave Marsh ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |